Literature DB >> 11733474

An extended interval dosing method for gentamicin in neonates.

M D Stickland1, C M Kirkpatrick, E J Begg, S B Duffull, S J Oddie, B A Darlow.   

Abstract

Traditional gentamicin dosing every 8-24 h depending on age and weight in neonates does not provide the ideal concentration-time profile to both optimize the concentration-dependent killing by aminoglycosides and minimize toxicity. Fifty-three neonates were audited prospectively while receiving gentamicin 2.5 mg/kg every 8-24 h, aiming for peak concentrations (Cmax) of 6-10 mg/L and trough concentrations (Cmin) <2 mg/L. After the first dose, the mean (+/- s.d.) Cmax was 5.5 +/- 0.7 mg/L with sub-therapeutic concentrations (<6 mg/L) in 62% of patients, while the mean Cmin was >2 mg/L in 15% of the neonates. After the third dose the Cmax was 7.5 +/- 1.5 mg/L, with 17% <6 mg/L, whereas the mean Cmin was 2.2 +/- 1.1 mg/L with 49% of values >2 mg/L. An extended interval dosing method (24, 36 and 48 h) for infant weights of 0.75-5 kg was developed by simulation, and audited prospectively in 51 neonates. Prospective analysis of the extended interval dosing method showed a mean Cmax after the first dose of 13.1 +/- 3.6 mg/L, while the mean Cmin was 0.7 +/- 0.6 mg/L. Seventy-eight per cent had Cmax of >10 mg/L after the first dose. The mean area under the concentration versus time curve AUC0-24 was 93 mg*h/L (target = 100 mg*h/L). The extended interval dosing achieved higher Cmax values while ensuring that overall exposure per 24 h was acceptable. Prospective testing of the method demonstrated good predictive ability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733474     DOI: 10.1093/jac/48.6.887

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  The effect of sepsis upon gentamicin pharmacokinetics in neonates.

Authors:  M Lingvall; D Reith; R Broadbent
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

2.  The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.

Authors:  Lena E Friberg; Geoffrey K Isbister; L Peter Hackett; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

3.  Extended-interval gentamicin dosing in achieving therapeutic concentrations in malaysian neonates.

Authors:  Yee Shan Low; Sin Li Tan; Angeline Sl Wan
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

Review 4.  One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.

Authors:  Shripada C Rao; Ravisha Srinivasjois; Kwi Moon
Journal:  Cochrane Database Syst Rev       Date:  2016-12-06

5.  Accuracy of empiric gentamicin dosing guidelines in neonates.

Authors:  Anna E Hitron; Yao Sun; Sarah B Scarpace
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

6.  Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.

Authors:  Aline Fuchs; Monia Guidi; Eric Giannoni; Dominique Werner; Thierry Buclin; Nicolas Widmer; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

7.  A Bayesian approach for population pharmacokinetic modelling of sirolimus.

Authors:  Chantaratsamon Dansirikul; Raymond G Morris; Susan E Tett; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

Review 8.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  High-dose gentamicin in newborn infants: is it safe?

Authors:  Jon Widding Fjalstad; Einar Laukli; John N van den Anker; Claus Klingenberg
Journal:  Eur J Pediatr       Date:  2013-11-14       Impact factor: 3.183

Review 10.  Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.

Authors:  Gary L Darmstadt; Mary Miller-Bell; Maneesh Batra; Paul Law; Kiely Law
Journal:  J Health Popul Nutr       Date:  2008-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.